A study out of Oslo, Norway, published in the New England Journal of Medicine questioned the effectiveness of colonoscopy in preventing colorectal cancer, the second deadliest cancer in the United States. The study triggered a swell of media reports casting doubt on the procedure.
If someone told me I’d have my first colonoscopy at 33, I wouldn’t have believed them. As an avid CrossFit athlete and circus artist, I pride myself on being healthy and in tip-top-shape.
The Alliance continues to ask its allies and the healthcare community to help advance its mission to end colorectal cancer in our lifetime — by spreading awareness and getting screened.
The test is for patients who are age 45 and older and who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC.
Two stories occurring decades apart bookend one Virginia survivor’s journey with colorectal cancer. The first story takes place shortly before humans walked on the moon. The last happened just the other day.
While more than 20 million additional people will be able to get a preventive colorectal cancer screening, most at no cost, this change will not catch every colorectal cancer. We still have work to do.
A study this month by the Alliance of Community Health Plans and Academy of Managed Care Pharmacies shows that due to concerns about the COVID-19 virus Americans have altered their use of traditional health services with many delaying necessary care.
Dr. Andrew Albert—recently named by StreetWise as one of the “2018 Most Inspiring Chicagoans” for his work launching the grassroots awareness campaign #backoffcoloncancer—offers his thoughts on colorectal cancer screening.
Early in 2018, the American Cancer Society (ACS) lowered its recommended colorectal cancer screening start age from 50 to 45. The news made the popular headlines and may have prompted the question:What is the ACS and why do these recommendations matter? These are important questions to ask. As healthcare consumers, you’re encouraged to know your options and empower yourselves with updated and balanced information.
When it comes to advocating for your health, understanding available options and what makes the most sense for your lifestyle, is key. An educated decision is always best.
This month, the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Decision for Cologuard, making it the first FDA-approved stool DNA test for the detection of colon cancer and precancer covered for Medicare patients throughout the country.
We were thrilled to see all the conversation around the recent announcement about the FDA clearance of Given Imaging’s PillCam COLON as a new colon exam tool.